Provention Bio: Provention Bio Q4 2022 Earnings Preview (NASDAQ:PRVB)
Provention Bio (PRVB) is scheduled to announce Q4 earnings results on Thursday, March 16th, before market open.The consensus EPS Estimate is -$0.43 and the consensus Revenue Estimate...
Read full article »
Provention Bio is a New Jersey-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of autoimmune diseases.
Read more